Home » Patent Issued for Allos Therapeutics’ Cancer Drug Folotyn
Patent Issued for Allos Therapeutics’ Cancer Drug Folotyn
Colorado biotech firm Allos Therapeutics Inc. said Monday that a patent has been issued for the use of its key product, the cancer
drug Folotyn, to treat T-cell lymphoma.
Denver Business Journal
Denver Business Journal
Upcoming Events
-
07May
-
14May
-
30May